Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Andrés Felipe Escobar González: Developing Anticoagulants That Prevent Thrombosis While Preserving Hemostasis
Nov 7, 2026, 23:59

Andrés Felipe Escobar González: Developing Anticoagulants That Prevent Thrombosis While Preserving Hemostasis

Andrés Felipe Escobar González, Pediatric Hematologist, Hemophilia Program at Medicarte, shared a post on LinkedIn about a recent article by Surasak Wichaiyo, published in JTH, adding:

“Received: 7 May 2026 – Revised: 9 July 2026 – Accepted: 3 August 2026

Educational Review

Pharmacology of anticoagulants: from heparin to novel target – specific agents

Surasak Wichaiyo

Anticoagulation therapy has undergone a remarkable evolution, from traditional agents such as heparin and vitamin K antagonists to direct oral anticoagulants and emerging therapies targeting specific coagulation factors.

In this review, ‘Pharmacology of Anticoagulants: From Heparin to Novel Target-Specific Agents,’ Surasak Wichaiyo explores the pharmacological mechanisms, clinical applications, and future perspectives of anticoagulant therapy, highlighting the growing interest in factor XI and XII inhibition.

One of the most exciting challenges in modern thrombosis research is developing anticoagulants that effectively prevent pathological thrombus formation while preserving physiological hemostasis and minimizing bleeding complications.

This evolving therapeutic landscape may open new opportunities for patients at high risk of both thrombosis and bleeding.”

Title: Pharmacology of anticoagulants: from heparin to novel target-specific agents

Authors: Surasak Wichaiyo

Andrés Felipe Escobar González

Stay updated on all scientific advances with Hemostasis Today.